Chiome Bioscience Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Chiome Bioscience has been growing earnings at an average annual rate of 5.2%, while the Life Sciences industry saw earnings growing at 25.6% annually. Revenues have been growing at an average rate of 17.3% per year.
Key information
5.2%
Earnings growth rate
17.2%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | 17.3% |
| Return on equity | -105.4% |
| Net Margin | -178.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Chiome Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 682 | -1,220 | 552 | 1,052 |
| 30 Sep 23 | 721 | -1,134 | 523 | -113 |
| 30 Jun 23 | 711 | -1,136 | 499 | 0 |
| 31 Mar 23 | 672 | -978 | 489 | 0 |
| 31 Dec 22 | 631 | -1,243 | 472 | 0 |
| 30 Sep 22 | 605 | -1,665 | 474 | 1,312 |
| 30 Jun 22 | 606 | -1,842 | 469 | 1,312 |
| 31 Mar 22 | 595 | -1,812 | 435 | 1,096 |
| 31 Dec 21 | 713 | -1,480 | 445 | 1,312 |
| 30 Sep 21 | 710 | -1,049 | 426 | 1,066 |
| 30 Jun 21 | 693 | -966 | 394 | 1,007 |
| 31 Mar 21 | 636 | -1,029 | 380 | 1,030 |
| 31 Dec 20 | 481 | -1,294 | 372 | 1,157 |
| 30 Sep 20 | 477 | -1,322 | 365 | 1,207 |
| 30 Jun 20 | 480 | -1,383 | 379 | 1,272 |
| 31 Mar 20 | 475 | -1,399 | 400 | 1,279 |
| 31 Dec 19 | 448 | -1,404 | 388 | 1,299 |
| 30 Sep 19 | 353 | -1,776 | 398 | 1,588 |
| 30 Jun 19 | 261 | -1,688 | 410 | 1,230 |
| 31 Mar 19 | 231 | -1,663 | 392 | 1,388 |
| 31 Dec 18 | 213 | -1,534 | 420 | 1,230 |
| 31 Dec 17 | 260 | -883 | 470 | 592 |
| 31 Dec 14 | 377 | -1,116 | 340 | 1,016 |
| 30 Sep 14 | 362 | -978 | 422 | 801 |
| 30 Jun 14 | 398 | -857 | 473 | 617 |
| 31 Mar 14 | 434 | -757 | 527 | 442 |
Quality Earnings: 4583 is currently unprofitable.
Growing Profit Margin: 4583 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4583 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.
Accelerating Growth: Unable to compare 4583's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4583 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-14.9%).
Return on Equity
High ROE: 4583 has a negative Return on Equity (-105.38%), as it is currently unprofitable.